A61P 5/32
Antioestrogens
A61P5/32 (Antioestrogens) appears on 341 US grants and 428 published applications in this corpus.
Search patents in A61P- Granted patents
- 341
- Published applications
- 428
- Assignees
- 194
- Inventors
- 834
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 8 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 6 | 0 |
| 2000 | 16 | 0 |
| 2001 | 19 | 6 |
| 2002 | 19 | 17 |
| 2003 | 18 | 45 |
| 2004 | 17 | 37 |
| 2005 | 14 | 31 |
| 2006 | 16 | 19 |
| 2007 | 7 | 17 |
| 2008 | 15 | 23 |
| 2009 | 9 | 32 |
| 2010 | 15 | 13 |
| 2011 | 13 | 26 |
| 2012 | 13 | 19 |
| 2013 | 13 | 20 |
| 2014 | 13 | 14 |
| 2015 | 14 | 13 |
| 2016 | 10 | 16 |
| 2017 | 16 | 16 |
| 2018 | 6 | 11 |
| 2019 | 13 | 15 |
| 2020 | 11 | 8 |
| 2021 | 4 | 7 |
| 2022 | 5 | 5 |
| 2023 | 2 | 5 |
| 2024 | 1 | 7 |
| 2025 | 1 | 3 |
| 2026 | 3 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination therapy using ribociclib and fulvestrant for the treatment of HR+ breast cancer10 Feb 2026US 12,544,379 B2Novartis AG
- Combination therapy using ribociclib and an aromatase inhibitor for the treatment of HR+ breast cancer10 Feb 2026US 12,544,380 B2Novartis AG
- Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof10 Feb 2026US 12,545,640 B2Sanofi
- Selective estrogen receptor degraders and uses thereof7 Jan 2025US 12,187,736 B2Inventisbio Co., Ltd.
- Methods for preparing antibody drug conjugates17 Sep 2024US 12,090,211 B2Genentech, Inc.
- Liquid formulation comprising trilostane20 Aug 2026US 2026/0240770 A1Norbrook Laboratories Limited
- Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof26 Feb 2026US 2026/0055080 A1
- Novel substituted benzothiophene-6-carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof26 Feb 2026US 2026/0055089 A1
- Therapeutically active steroidal derivatives21 Aug 2025US 2025/0263431 A1Organon R&D Finland Ltd.
- Combination therapy for the treatment of cancer5 Jun 2025US 2025/0177402 A1Novartis AG
Most cited
By later US patents
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995
- 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis98US 5,552,412 APfizer Inc. · 1996
- Organic compounds95US 8,664,207 B2Intra-Cellular Therapies, Inc. · 2014
- Benzothiophene derivative80US 5,472,962 ATeikoku Hormone Mfg. Co., Ltd. · 1995
- Selective estrogen receptor modulator79US 7,612,114 B2Eisai R&D Management Co., Ltd. · 2009